Theriva Biologics, Inc. · AMEX:TOVX
Theriva Biologics — Synthetic Biologics — Investor Presentation (December 2021)
26 slides from Theriva Biologics's investor presentation, December 2021
Slide 1: Synthetic Biologics, Inc.
Synthetic Biologics, Inc. December 2021 Updated 11.23.2021 www.syntheticbiologics.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be i
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights Pipeline of GI-focused assets which couple our formulary and Focused Clinical Strategy manufacturing expertise with feasible and efficient clinical development strategies Diversified clinical-stage company leveraging the microbiome Targeted GI Therapeutics to develop
Slide 4: Management
Management Executive Team Advisory Team Eric Dubberke, MD, MSPH Steven Shallcross, MBA, CPA SYN-004 Phase 1b/2a Chief Executive and Financial Officer Co-Principle Investigator Mark A. Schroeder, MD Michael Kaleko, MD, PhD SYN-004 Phase 1b/2a Co-Principle Investigator Senior Vice President, R&D Richa
Slide 5: Broadly Applicable Modalities
Broadly Applicable Modalities Focus Area Candidate Indication IND-Enabling Phase 1 Phase 2 Collaborator Status* FDA-agreed Microbiome SYN-004¹ CDI & AMR Prevention Phase 3 program² & Infection SYN-004¹ aGVHD in allo-HCT FDA-agreed Ongoing Phase 1b/2a Study Topline data Q1 ‘22 Ongoing SYN-020 Celiac
Slide 6: SYN-004 (ribaxamase)
SYN-004 (ribaxamase) Prevention of aGVHD in Hematopoietic Cell Transplant
Slide 7: The Gut Microbiome and Disease Prevention
The Gut Microbiome and Disease Prevention • The gut microbiome is a complex community of ~39 trillion microbes in our gastrointestinal tract¹ • Predominantly reside in the colon • The microbiome is integral to our health² • Cancer, CNS, GI, immune system, infection, metabolism • Antibiotic damage to
Slide 8: Antibiotics can Damage the Microbiome
Antibiotics can Damage the Microbiome Antibiotic use worldwide β-Lactam and Carbapenem Antibiotics Some of the worst intestinal microbiome damaging agents ALL Antibiotics IV, PO Cephalosporins IV Cephalosporins IV, PO Penicillins IV Penicillins ~64% of the World’s antibiotics IV Carbapenems ~57% of
Slide 9: SYN-004 (ribaxamase) to Prevent Dysbiosis
SYN-004 (ribaxamase) to Prevent Dysbiosis β-lactam antibiotic excreted into the GI tract can cause dysbiosis Treat Primary Infection (e.g. pneumonia) Systemic (IV) Antibiotic β-lactam antibiotic Excreted in Bile Stomach Duodenum Jejunum Ileum Cecum Colon ANTIBIOTIC EFFECTS û Disrupted microbiome û P
Slide 10: SYN-004 (ribaxamase) to Prevent Dysbiosis
SYN-004 (ribaxamase) to Prevent Dysbiosis Degrading excess β-lactam antibiotic excreted into the GI tract Treat Primary Infection (e.g. pneumonia) Systemic (IV) Antibiotic β-lactam antibiotic Excreted in Bile SYN-004 Stomach Duodenum Jejunum Ileum Cecum Colon (ribaxamase) TARGET OUTCOMES ü Restore h
Slide 11: SYN-004 (ribaxamase) Prior Regulatory Interaction
SYN-004 (ribaxamase) Prior Regulatory Interaction EOP2 meeting held with FDA Q3 2018 to discuss CDI Prevention • Phase 3 program in CDI prevention may comprise a single, large, global, multicenter, randomized controlled clinical trial • Primary efficacy endpoint reduction of CDI incidence in SYN-004
Slide 12: SYN-004 (ribaxamase) Status and Strategy
SYN-004 (ribaxamase) Status and Strategy • Advance SYN-004 in alternate clinical indication(s) with higher incidence endpoints and smaller anticipated clinical trials • Prevention of aGVHD and improving aGVHD-free survival¹ in allogeneic hematopoietic cell transplant (allo-HCT) recipients • Secondar
Slide 13: Allogeneic Hematopoietic Cell Transplantation (HCT)
Allogeneic Hematopoietic Cell Transplantation (HCT) • IV β-lactam antibiotics are used in 80-90% of allogeneic HCT recipients in response to neutropenic fever¹ • Microbiome damage by IV β-lactam antibiotics is associated with aGVHD, VRE colonization/bacteremia, CDI²-⁶ • aGVHD occurs in 30-60% of all
Slide 14: SYN-004 (ribaxamase) Allogeneic HCT Opportunity
SYN-004 (ribaxamase) Allogeneic HCT Opportunity Potential to save lives and reduce costs • Over 9,000 allogeneic HCT procedures in the USA in 2018-19¹ • Estimated 19,800 procedures in Europe; 9,600 in China; 3,500 in Japan²-⁴ • USA in-patient costs of $180,000 to >$300,000 per allogeneic-HCT patient
Slide 15: Ongoing SYN-004 Phase 1b/2a Trial in Allogeneic HCT
Ongoing SYN-004 Phase 1b/2a Trial in Allogeneic HCT Treatment Follow-up Primary Outcomes (T1-T3) Consent Placebo (n=4) or SYN-004 PO (n=8) • SYN-004 safety and tolerability DSMC review: AEs, bacteremia, SYN-004 absorption, MER PK • SYN-004 systemic absorption (if any) Meropenem (MER) IV • IV β-lacta
Slide 16: SYN-004 (ribaxamase) Development Strategy
SYN-004 (ribaxamase) Development Strategy • Potential Orphan Drug designation CDI, AMR • Payer = 1° value driver Infection Estimated Value • aGVHD costs borne by Payers Control (including patients) 4 • Greatest pricing flexibility se • Potential access to NTAP (USA) CDI, AMR Pha Solid Organ Transpla
Slide 17: SYN-020 Intestinal Alkaline Phosphatase
SYN-020 Intestinal Alkaline Phosphatase
Slide 18: Intestinal Alkaline Phosphatase
Intestinal Alkaline Phosphatase A naturally-occurring protein with the unique capacity to treat many diseases • IAP is a naturally-occurring enzyme • Maintains gastrointestinal produced in the small intestine homeostasis¹,² • 150 kD homodimer coordinating Mg2+ and Zn2+ • Detoxifies inflammatory medi
Slide 19: IAP has Demonstrated Efficacy in Animals and Humans
IAP has Demonstrated Efficacy in Animals and Humans Model Outcome Humans Ulcerative Colitis Clinical improvement in refractory UC at 21 days after 1 week of cIAP nasoduodenal infusion¹ Type 1 Diabetes T1DM patients had decreased IAP activity in stool; oral IAP supplementation may suppress low-grade
Slide 20: Overcoming Key IAP Development Challenges
Overcoming Key IAP Development Challenges Synthetic Biologics expertise in protein manufacture and oral delivery • Manufacturing has limited the clinical progress of oral IAP • cIAP is extracted from calf intestine and requires extensive purification, costing up to $10,000/g¹ • IAP yields are very l
Slide 21: SYN-020 Prevents Gut Damage from Radiation
SYN-020 Prevents Gut Damage from Radiation C57Bl/6 mice administered a single dose of whole-body irradiation SYN-020 prevented shortening of villi and inflammatory infiltrates (left) and preserved endogenous levels of IAP mRNA (Akp3; right) in the intestinal tissue of mice treated with total body ir
Slide 22: SYN-020 Reduces Radiation-Induced Inflammation
SYN-020 Reduces Radiation-Induced Inflammation C57Bl/6 mice administered a single dose of whole-body irradiation SYN-020 preserved gut barrier function (FITC-Dextran assay; A), maintained expression levels of the tight junction protein zonulin (B) and reduced inflammation (cytokines; C-E) in mice tr
Slide 23: SYN-020 Development Status
SYN-020 Development Status • Clinical • Completed Phase 1 single ascending dose (SAD) study in healthy volunteers ‒ SYN-020 maintained a favorable safety profile and was well tolerated at all dose levels ‒ No adverse events were attributed to SYN-020 and no SAEs were reported ‒ 24 healthy adult volu
Slide 24: SYN-020 Clinical Program Expansion
SYN-020 Clinical Program Expansion • Entered into a research agreement with Massachusetts General Hospital (MGH) • Exclusive option to license I.P. and technology for use of SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging • Expected to expand upon foundational
Slide 25: Financial Snapshot
Financial Snapshot Current SYN Snapshot Synthetic Biologics, Inc. Current Capitalization Table Exchange NYSE American (Sept. 30, 2021) Ticker SYN Common Shares Outstanding 132,042,538 Current Cash (as of 9/30/2021) ~$72.1 million Stock Options Issued (2007, 2010 & 3,997,418 Average Daily Volume (3M
Slide 26: Thank You
Thank You www.syntheticbiologics.com
Synthetic Biologics — Investor Presentation (December 2021) on 6ix